Taysha Gene Therapies, Inc.(TSHA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

TSHA Taysha Gene Therapies, Inc.

Post-Mkt 09-23 16:34:53 EDT

4.91

-0.25

-4.84%

盘后4.90

-0.01-0.17%

16:27 EDT

High5.14	Low4.88	Vol5.51M
Open5.11	D1 Closing5.16	Amplitude5.04%
Mkt Cap1.60B	Tradable Cap1.14B	Total Shares325.83M
T/O27.24M	T/O Rate2.36%	Tradable Shares233.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"TSHA","market":"US","secType":"STK","nameCN":"Taysha Gene Therapies, Inc.","latestPrice":4.91,"timestamp":1790193600000,"preClose":5.16,"halted":0,"volume":5506171,"hourTrading":{"tag":"盘后","latestPrice":4.9017,"preClose":4.91,"latestTime":"16:27 EDT","volume":16817,"amount":82578.449055,"timestamp":1790195273683,"change":-0.0083,"changeRate":-0.00169,"amplitude":0.005764},"delay":0,"changeRate":-0.04844961240310077,"floatShares":233000000,"shares":325833545,"eps":-0.4126,"marketStatus":"Post-Mkt","change":-0.25,"latestTime":"09-23 16:34:53 EDT","open":5.11,"high":5.14,"low":4.88,"amount":27235943,"amplitude":0.050388,"askPrice":5.02,"askSize":100,"bidPrice":4.9,"bidSize":317,"shortable":3,"etf":0,"ttmEps":-0.4126,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1790208000000},"marketStatusCode":4,"adr":0,"listingDate":1600920000000,"exchange":"NASDAQ","adjPreClose":5.16,"preHourTrading":{"tag":"盘前","latestPrice":5.18,"preClose":5.16,"latestTime":"09:18 EDT","volume":6,"amount":31.200000000000003,"timestamp":1790169499499,"change":0.02,"changeRate":0.003876,"amplitude":0.011628},"postHourTrading":{"tag":"盘后","latestPrice":4.9017,"preClose":4.91,"latestTime":"16:27 EDT","volume":16817,"amount":82578.449055,"timestamp":1790195273683,"change":-0.0083,"changeRate":-0.00169,"amplitude":0.005764},"volumeRatio":1.278857,"impliedVol":0.3861,"impliedVolPercentile":0.0797},"requestUrl":"/m/hq/s/TSHA/tweets","defaultTab":"tweets","newsList":[{"id":"2668296256","title":"Wolfe Research Initiates Taysha Gene Therapies at Outperform","url":"https://stock-news.laohu8.com/highlight/detail?id=2668296256","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668296256?lang=en_us&edition=fundamental","pubTime":"2026-09-17 20:24","pubTimestamp":1789647865,"startTime":"0","endTime":"0","summary":"Taysha Gene Therapies (TSHA) has an average rating of buy and mean price target of $13, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TSHA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668613629","title":"Taysha Gene Therapies initiated with an Outperform at Wolfe Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2668613629","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668613629?lang=en_us&edition=fundamental","pubTime":"2026-09-17 19:20","pubTimestamp":1789644033,"startTime":"0","endTime":"0","summary":"Wolfe Research initiated coverage of Taysha Gene Therapies (TSHA) with an Outperform rating. Published first on TheFly – the ultimate source for re...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/taysha-gene-therapies-initiated-with-an-outperform-at-wolfe-research-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/taysha-gene-therapies-initiated-with-an-outperform-at-wolfe-research-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TSHA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664331659","title":"Taysha Gene Therapies Grants New Hires 314,000 RSUs, 92,400 Options at $5.7 Strike","url":"https://stock-news.laohu8.com/highlight/detail?id=2664331659","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664331659?lang=en_us&edition=fundamental","pubTime":"2026-09-04 20:01","pubTimestamp":1788523263,"startTime":"0","endTime":"0","summary":"Taysha Gene Therapies grants new hires 314,000 RSUs, 92,400 options at $5.7 strikeTaysha Gene Therapies granted five new employees 314,000 restricted stock units, representing shares of common stock.I","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260904:nNDL758ZbW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","LU2210149790.SGD","BK4139","IE00BN0W2W23.USD","IE00BQXX3C00.GBP","IE00B3QW5Z07.USD","IE00BQXX3F31.USD","IE00BN0W2T93.GBP","SG9999014013.SGD","BK4585","LU2095319765.USD","LU2210150020.SGD","SG9999014005.SGD","LU0314104364.USD","BK4588","TSHA","IE00BGHQF748.EUR","SG9999014021.USD","IE00BN0W2V16.EUR","BK4112","SG9999014039.USD","IE00B64PRP62.GBP","IE00BKPKM429.USD","IE00BQXX3D17.EUR","BCDF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664331553","title":"Taysha Gene Therapies Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2664331553","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664331553?lang=en_us&edition=fundamental","pubTime":"2026-09-04 20:00","pubTimestamp":1788523201,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260904:nTUA4GYNM2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TSHA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664331917","title":"Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2664331917","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664331917?lang=en_us&edition=fundamental","pubTime":"2026-09-04 20:00","pubTimestamp":1788523200,"startTime":"0","endTime":"0","summary":"DALLAS, Sept.  04, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/04/3356521/0/en/taysha-gene-therapies-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TSHA","BK4135","LCLG","CNS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664005840","title":"Taysha Gene Therapies Highlights TSHA-102 Rett Gene Therapy Path Toward BLA Submission in Corporate Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2664005840","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664005840?lang=en_us&edition=fundamental","pubTime":"2026-09-01 02:26","pubTimestamp":1788200761,"startTime":"0","endTime":"0","summary":"Taysha Gene Therapies highlights TSHA-102 Rett gene therapy path toward BLA submission in corporate presentationTaysha Gene Therapies outlined an accelerated registration plan for TSHA-102, a one-time","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nNDLbd52Ct:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TSHA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659460154","title":"MeiraGTx Q2 Revenue Jumps on Reogen License Revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2659460154","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659460154?lang=en_us&edition=fundamental","pubTime":"2026-08-13 20:22","pubTimestamp":1786623742,"startTime":"0","endTime":"0","summary":"MeiraGTx Q2 revenue jumps on Reogen license revenueOverviewUK-U.S. genetic medicines firm's Q2 revenue surgedCompany posted net income after a loss in the prior-year quarterMeiraGTx completed bota-vec","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A0JP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MGTX","RCKT","TSHA","BK4139","ABEO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659014159","title":"Abeona Therapeutics Q2 Net Loss Widens, Misses Analyst Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2659014159","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659014159?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:39","pubTimestamp":1786621195,"startTime":"0","endTime":"0","summary":"Abeona Therapeutics Q2 net loss widens, misses analyst expectationsOverviewUS cell and gene therapy firm's Q2 net ZEVASKYN revenue rose 31% quarter-over-quarterQ2 net loss and loss per share missed an","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A0IC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","TSHA","BK4505","ABEO","BK4139","IPSC","RCKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659130468","title":"Taysha Gene Therapies (TSHA) Stock Trades At A Premium Despite A 232% Return","url":"https://stock-news.laohu8.com/highlight/detail?id=2659130468","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659130468?lang=en_us&edition=fundamental","pubTime":"2026-08-13 16:31","pubTimestamp":1786609860,"startTime":"0","endTime":"0","summary":"Taysha Gene Therapies stock has delivered a very strong 231.9% return over the past three years, yet current valuation checks and market multiples point to a less straightforward picture of whether the recent gains leave enough room for upside from here.\n\nThe stock is up 231.9% over three years, which puts extra weight on whether recent optimism about its gene therapy pipeline is already reflected in the share price.\nProgress on TSHA-102 for Rett syndrome, including completed dosing in key...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tsha/taysha-gene-therapies/news/taysha-gene-therapies-tsha-stock-trades-at-a-premium-despite","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tsha/taysha-gene-therapies/news/taysha-gene-therapies-tsha-stock-trades-at-a-premium-despite","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CDIG","TACU","TSHA","TSPA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659885111","title":"Turn Therapeutics Q2 Net Loss Per Share Widens on Higher R&D Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2659885111","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659885111?lang=en_us&edition=fundamental","pubTime":"2026-08-13 04:39","pubTimestamp":1786567166,"startTime":"0","endTime":"0","summary":"Turn Therapeutics Q2 net loss per share widens on higher R&D costsOverviewUS biotechnology firm's Q2 net loss per share widened yr/yr as R&D expenses increasedCompany expanded GX-03 Phase 2 study afte","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL1N44913J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSHA","BK4139","TTRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659092299","title":"U.S. Stocks on the MOVE-Sutro Biopharma, Humacyte","url":"https://stock-news.laohu8.com/highlight/detail?id=2659092299","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659092299?lang=en_us&edition=fundamental","pubTime":"2026-08-13 00:17","pubTimestamp":1786551433,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Sutro Biopharma, HumacyteAugust 12 (Reuters)-Wall Street's main indexes rose on Wednesday, with the Nasdaq outperforming peers as upbeat earnings from AI infrastructure fi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL6N4490YK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALT","SMWB","UAMY","WXM","CHTR","OFAL","NBIS","CAVA","DFTX","LUMA","SMMT","SVV","BIVI","PFGC","O","BETA","EAT","GAP","UFO","SMCL","EROC","CRWV","LOCL","NBIX","STRO","TAN","HUMA","LAZR","TRMB","FSLR","ANNX","TSHA","NBIZ","HRB","SLXN","LITE","SLNCF","TECH","DPRE","NCMI","CORD","SMCI","CIEN","OPLN","NTHI","TPL","ABSI","LQDA","SLN","EGGY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658051869","title":"Cantor Fitzgerald Keeps Their Buy Rating on Taysha Gene Therapies (TSHA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658051869","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658051869?lang=en_us&edition=fundamental","pubTime":"2026-08-12 22:35","pubTimestamp":1786545329,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Kristen Kluska from Cantor Fitzgerald maintained a Buy rating on Taysha Gene Therapies, with a price target of $19....","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/cantor-fitzgerald-keeps-their-buy-rating-on-taysha-gene-therapies-tsha-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/cantor-fitzgerald-keeps-their-buy-rating-on-taysha-gene-therapies-tsha-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TSHA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658037289","title":"Wall Street Analysts Are Bullish on Top Healthcare Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2658037289","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658037289?lang=en_us&edition=fundamental","pubTime":"2026-08-12 22:10","pubTimestamp":1786543809,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Taysha Gene Therapies (TSHA), IQVIA Holdings (IQV) a...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-296?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-296?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EKG","LU0130517989.USD","LU1261432733.SGD","LU0980610538.SGD","LU0198837287.USD","LU0528227936.USD","LU1201861165.SGD","BK4139","LU1989764664.SGD","LU0477156953.USD","LU0130103400.USD","BK4530","LU0648000940.SGD","HEAL","BK4588","LU1989764748.USD","BK4121","TSHA","LU0882574055.USD","LU1201861249.SGD","LU0477156797.USD","LU0130518102.USD","LU1791710582.SGD","LU0648001328.SGD","LU0130102774.USD","LU1791710400.SGD","IQV","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658972452","title":"Taysha Falls on Wider-than-Expected Quarterly Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2658972452","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658972452?lang=en_us&edition=fundamental","pubTime":"2026-08-12 20:11","pubTimestamp":1786536662,"startTime":"0","endTime":"0","summary":"BUZZ-Taysha falls on wider-than-expected quarterly loss** Shares of Taysha Gene TherapiesTSHA.Ofall 8.7% to $6.10 premarket** Co reportsQ2 net loss of $46.6 millionvs analysts' average loss estimate o","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL4N4490X1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TSHA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658797488","title":"Piper Sandler Sticks to Their Buy Rating for Taysha Gene Therapies (TSHA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2658797488","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658797488?lang=en_us&edition=fundamental","pubTime":"2026-08-12 19:06","pubTimestamp":1786532808,"startTime":"0","endTime":"0","summary":"In a report released today, Biren Amin from Piper Sandler maintained a Buy rating on Taysha Gene Therapies, with a price target of $12.00. Accordin...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/piper-sandler-sticks-to-their-buy-rating-for-taysha-gene-therapies-tsha-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/piper-sandler-sticks-to-their-buy-rating-for-taysha-gene-therapies-tsha-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TSHA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658945256","title":"Taysha Gene Therapies, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2658945256","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658945256?lang=en_us&edition=fundamental","pubTime":"2026-08-12 05:00","pubTimestamp":1786482047,"startTime":"0","endTime":"0","summary":"Taysha Gene Therapies, Inc. reports results for the quarter ended June 30 - Earnings SummaryTaysha Gene Therapies, Inc.TSHA.OQreported a quarterly adjusted loss of 14 cents per share for the quarter e","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nL8N44825T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSHA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658454659","title":"Taysha Gene Therapies Q2 Loss Widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2658454659","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658454659?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:56","pubTimestamp":1786481791,"startTime":"0","endTime":"0","summary":"Taysha Gene Therapies  reported Q2 net loss late Tuesday of $0.13 per diluted share, compared with a loss of $0.09 per diluted share a year earlier.Analysts polled by FactSet expected a loss of $0.11.The company reported no revenue for the quarter ended June 30, compared with about $2 million a year earlier.Analysts polled by FactSet expected $700,000.As of June 30, the company said it had cash and cash equivalents of $455.4 million, expected to fund operating expenses and capital requirements through H2 of 2028.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TSHA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658437629","title":"Earnings Flash (TSHA) Taysha Gene Therapies Posts Q2 Loss of $0.13, vs. FactSet Est of $0.11 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2658437629","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658437629?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:30","pubTimestamp":1786480258,"startTime":"0","endTime":"0","summary":"Earnings Flash (TSHA) Taysha Gene Therapies Posts Q2 Loss of $0.13, vs. FactSet Est of $0.11 Loss","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TSHA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658334943","title":"Taysha Gene Therapies Q2 Net Income USD -46.639 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2658334943","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658334943?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:14","pubTimestamp":1786479256,"startTime":"0","endTime":"0","summary":"Aug 11 (Reuters) - Taysha Gene Therapies Q2 operating expenses USD 47.349 million.:((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))Source Date/Time = 11-AUG-202620:01:00.61 GMT","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nRSD9jnDb0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TSHA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658948341","title":"Taysha Gene Therapies Q2 EPS $(0.13) Misses $(0.12) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2658948341","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658948341?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:00","pubTimestamp":1786478451,"startTime":"0","endTime":"0","summary":"Taysha Gene Therapies (NASDAQ:TSHA) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.12) by 8.33 percent. This is a 44.44 percent decrease over losses of $(0.09) per","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61125289/taysha-gene-therapies-q2-eps-0-13-misses-0-12-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Taysha Gene Therapies Q2 EPS $(0.13) Misses $(0.12) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSHA"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tayshagtx.com","stockEarnings":[{"period":"1week","weight":0.0198},{"period":"1month","weight":-0.1527},{"period":"3month","weight":-0.2565},{"period":"6month","weight":0.1944},{"period":"1year","weight":0.7979},{"period":"ytd","weight":-0.0618}],"compareEarnings":[{"period":"1week","weight":0.0211},{"period":"1month","weight":0.01},{"period":"3month","weight":0.0547},{"period":"6month","weight":0.1989},{"period":"1year","weight":0.1598},{"period":"ytd","weight":0.1341}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.177745},{"month":2,"riseRate":0.5,"avgChangeRate":0.091899},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.104956},{"month":4,"riseRate":0.5,"avgChangeRate":0.079391},{"month":5,"riseRate":0.333333,"avgChangeRate":0.032889},{"month":6,"riseRate":0.333333,"avgChangeRate":0.002069},{"month":7,"riseRate":0.5,"avgChangeRate":-0.007161},{"month":8,"riseRate":0.666667,"avgChangeRate":0.622298},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.09018},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.04036},{"month":11,"riseRate":0.5,"avgChangeRate":0.137875},{"month":12,"riseRate":0.666667,"avgChangeRate":-0.034429}],"exchange":"NASDAQ","name":"Taysha Gene Therapies, Inc.","nameEN":"Taysha Gene Therapies, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Taysha Gene Therapies, Inc.(TSHA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Taysha Gene Therapies, Inc.(TSHA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Taysha Gene Therapies, Inc.,TSHA,Taysha Gene Therapies, Inc.股票,Taysha Gene Therapies, Inc.股票老虎,Taysha Gene Therapies, Inc.股票老虎国际,Taysha Gene Therapies, Inc.行情,Taysha Gene Therapies, Inc.股票行情,Taysha Gene Therapies, Inc.股价,Taysha Gene Therapies, Inc.股市,Taysha Gene Therapies, Inc.股票价格,Taysha Gene Therapies, Inc.股票交易,Taysha Gene Therapies, Inc.股票购买,Taysha Gene Therapies, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Taysha Gene Therapies, Inc.(TSHA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Taysha Gene Therapies, Inc.(TSHA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}